RETRACTION: lncRNA-PDPK2P Promotes Hepatocellular Carcinoma Progression Through the PDK1/AKT/Caspase 3 Pathway.

IF 6.6 2区 医学 Q1 Biochemistry, Genetics and Molecular Biology
{"title":"RETRACTION: lncRNA-PDPK2P Promotes Hepatocellular Carcinoma Progression Through the PDK1/AKT/Caspase 3 Pathway.","authors":"","doi":"10.1002/1878-0261.70044","DOIUrl":null,"url":null,"abstract":"<p><strong>Retraction: </strong>W. Pan, W. Li, J. Zhao, Z. Huang, J. Zhao, S. Chen, C. Wang, Y. Xue, F. Huang, Q. Fang, J. Wang, D. Brand, and S. G. Zheng, \"lncRNA-PDPK2P Promotes Hepatocellular Carcinoma Progression Through the PDK1/AKT/Caspase 3 Pathway,\" Molecular Oncology 13, no. 10 (2019): 2246-2258, https://doi.org/10.1002/1878-0261.12553. The above article, published online on 01 August 2019 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the journal Editor-in-Chief, Kevin Ryan; FEBS Press; and John Wiley & Sons Ltd. A third party reported to the journal that the one of the P-PDPK2P tumor images in Figure 2E appeared to exceed 2 cm in diameter, which exceeds the maximum size recommended by ARRIVE guidelines. Further investigation by the journal and the publisher also found evidence that the second and third P-NC mice in Figures 2E and 2F appeared to be the same mouse, although both were reported as having received different treatments. The authors responded to an inquiry by the publisher and provided original data. An evaluation of these data by the publisher further determined that there were several discrepancies between what was shown in the original data and what was reported in the published article. The authors stated that no mice had been reused between the images in Figures 2E and 2F. The authors also confirmed that one tumor image in Figure 2E exceeded 2 cm, but that the research was performed at the Third Affiliated Hospital at the Sun Yat-sen University and was in compliance with China's \"Guideline for Welfare and Ethical Review of Laboratory Animals\" (GB/T 35892-2018), which sets no tumor diameter limits for nude mice. The parties have determined that the authors violated ARRIVE guidelines governing the maximum size of tumor samples, which had been adopted by the journal at the time of submission. The parties have also determined that there is overwhelming evidence that two mouse subjects were reused in Figures 2E and 2F but were presented as having received different treatments. There were several other discrepancies between the original data provided by the authors and those presented in the published article. The retraction has been agreed to because the article did not conform to the ethical guidelines of the journal at the time of submission and because there is significant evidence that some data included in the article were inaccurate or misreported, which fundamentally compromises the editors' confidence in the conclusions presented. The authors did not indicate their agreement with the retraction.</p>","PeriodicalId":18764,"journal":{"name":"Molecular Oncology","volume":" ","pages":""},"PeriodicalIF":6.6000,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/1878-0261.70044","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}
引用次数: 0

Abstract

Retraction: W. Pan, W. Li, J. Zhao, Z. Huang, J. Zhao, S. Chen, C. Wang, Y. Xue, F. Huang, Q. Fang, J. Wang, D. Brand, and S. G. Zheng, "lncRNA-PDPK2P Promotes Hepatocellular Carcinoma Progression Through the PDK1/AKT/Caspase 3 Pathway," Molecular Oncology 13, no. 10 (2019): 2246-2258, https://doi.org/10.1002/1878-0261.12553. The above article, published online on 01 August 2019 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the journal Editor-in-Chief, Kevin Ryan; FEBS Press; and John Wiley & Sons Ltd. A third party reported to the journal that the one of the P-PDPK2P tumor images in Figure 2E appeared to exceed 2 cm in diameter, which exceeds the maximum size recommended by ARRIVE guidelines. Further investigation by the journal and the publisher also found evidence that the second and third P-NC mice in Figures 2E and 2F appeared to be the same mouse, although both were reported as having received different treatments. The authors responded to an inquiry by the publisher and provided original data. An evaluation of these data by the publisher further determined that there were several discrepancies between what was shown in the original data and what was reported in the published article. The authors stated that no mice had been reused between the images in Figures 2E and 2F. The authors also confirmed that one tumor image in Figure 2E exceeded 2 cm, but that the research was performed at the Third Affiliated Hospital at the Sun Yat-sen University and was in compliance with China's "Guideline for Welfare and Ethical Review of Laboratory Animals" (GB/T 35892-2018), which sets no tumor diameter limits for nude mice. The parties have determined that the authors violated ARRIVE guidelines governing the maximum size of tumor samples, which had been adopted by the journal at the time of submission. The parties have also determined that there is overwhelming evidence that two mouse subjects were reused in Figures 2E and 2F but were presented as having received different treatments. There were several other discrepancies between the original data provided by the authors and those presented in the published article. The retraction has been agreed to because the article did not conform to the ethical guidelines of the journal at the time of submission and because there is significant evidence that some data included in the article were inaccurate or misreported, which fundamentally compromises the editors' confidence in the conclusions presented. The authors did not indicate their agreement with the retraction.

结论:lncRNA-PDPK2P通过PDK1/AKT/Caspase 3通路促进肝细胞癌进展。
引用本文:潘伟,李伟,赵军,黄志杰,赵军,陈淑娟,王超,薛勇,黄峰,方强,王军,Brand d,郑树国,“lncRNA-PDPK2P通过PDK1/AKT/Caspase 3通路促进肝癌进展”,《中华肿瘤杂志》,第13期,no。10 (2019): 2246-2258, https://doi.org/10.1002/1878-0261.12553。上述文章于2019年8月1日在线发表在Wiley在线图书馆(wileyonlinelibrary.com)上,经主编Kevin Ryan同意撤回;2月出版社;及约翰威利父子有限公司。第三方向该杂志报告,图2E中P-PDPK2P肿瘤图像中的一个直径超过2cm,超过了ARRIVE指南推荐的最大尺寸。该杂志和出版商的进一步调查还发现,图2E和2F中的第二只和第三只P-NC小鼠似乎是同一只小鼠,尽管据报道,这两只小鼠接受了不同的治疗。作者回应了出版商的询问,并提供了原始数据。出版商对这些数据的评估进一步确定,原始数据中显示的内容与发表文章中报告的内容之间存在一些差异。作者指出,在图2E和图2F的图像之间没有重复使用小鼠。作者还确认了图2E中的一个肿瘤图像超过2厘米,但该研究是在中山大学第三附属医院进行的,并且符合中国《实验动物福利与伦理审查指南》(GB/T 35892-2018),该指南没有对裸鼠的肿瘤直径进行限制。双方已经确定,作者违反了在提交时已被该杂志采用的关于肿瘤样本最大尺寸的ARRIVE指南。双方还确定,有压倒性的证据表明,在图2E和2F中,两只小鼠受试者被重复使用,但被呈现为接受了不同的治疗。作者提供的原始数据与发表的文章中提供的数据之间还有其他一些差异。由于文章在提交时不符合期刊的伦理准则,并且有明显证据表明文章中包含的一些数据不准确或错误报道,这从根本上损害了编辑对所提出结论的信心,因此同意撤回。作者没有表明他们同意撤稿。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Molecular Oncology
Molecular Oncology Biochemistry, Genetics and Molecular Biology-Molecular Medicine
CiteScore
11.80
自引率
1.50%
发文量
203
审稿时长
10 weeks
期刊介绍: Molecular Oncology highlights new discoveries, approaches, and technical developments, in basic, clinical and discovery-driven translational cancer research. It publishes research articles, reviews (by invitation only), and timely science policy articles. The journal is now fully Open Access with all articles published over the past 10 years freely available.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信